Protocols

Current literature on GHK-Cu (copper tripeptide) administration protocols is limited, with most research being preclinical. The available evidence shows varied dosing approaches depending on the route of administration and therapeutic target.

Preclinical Dosing

In animal studies, GHK-Cu has been administered via multiple routes:

Intraperitoneal administration: Used in middle-aged mice studies, though specific dosages are not detailed in available abstracts
Intranasal administration: Also employed in mouse behavioral studies, with protocols showing potential for central nervous system effects
Topical application: Incorporated into hydrogels and microsphere delivery systems for wound healing applications

Clinical Applications

Limited clinical trial data is available:

Topical formulations: A Phase 2 clinical trial (NCT07437586) is currently recruiting participants to evaluate topical GHK-Cu gel for acute skin wound healing, though dosing protocols are not specified in public records
Cosmetic applications: Phase 4 trials have examined GHK-Cu in facial treatments, but specific concentrations and protocols remain proprietary

Route-Specific Considerations

The literature suggests different administration routes may produce distinct biological effects:

Systemic routes (intraperitoneal, intranasal) appear to target metabolic and neurological pathways
Topical applications focus primarily on wound healing and skin regeneration
Injectable hydrogel formulations are being developed for localized tissue repair

Evidence Limitations

The current evidence base lacks standardized dosing protocols across studies. Most research remains in preclinical phases, with limited human clinical data available for establishing optimal therapeutic dosing regimens.

This information is for educational purposes only and does not constitute personalized medical advice. Consult with a qualified healthcare provider before considering any therapeutic use of GHK-Cu.

GHK-Cu

Member access required